Mizushima, Tsunekazu
Udagawa, Eri
Hasegawa, Miyuki
Tazuke, Yuko
Okuyama, Hiroomi
Fernandez, Jovelle
Nakamura, Shiro
Funding for this research was provided by:
Takeda Pharmaceutical Company Limited
Article History
Received: 27 September 2021
Accepted: 26 December 2021
First Online: 23 February 2022
Declarations
:
: Tsunekazu Mizushima: research funding from Takeda Pharmaceutical Company Limited. The Department of Therapeutics for Inflammatory Bowel Diseases is supported by an unrestricted grant from Kinshukai Medical Corporation. Shiro Nakamura: honoraria from Takeda Pharmaceutical Company Limited, AbbVie Inc, Pfizer Japan Inc., Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd, Mochida pharmaceutical Co. Ltd, and Janssen Pharmaceutical Co. Ltd; research funding from Mitsubishi Tanabe Pharma Corporation. Eri Udagawa, Miyuki Hasegawa, and Jovelle Fernandez: employees of Takeda Pharmaceutical Company Limited. Jovelle Fernandez: owns stock in Takeda Pharmaceutical Company Limited and GSK. Hiroomi Okuyama: received fees for advisory and promotional materials (e.g., manuscript) from Takeda Pharmaceutical Company Limited. Yuko Tazuke: no conflict of interest to declare.